EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Impact BioMedical, Inc. (IBO) fair value: what the stock is really worth

We calculate from audited financials what Impact BioMedical, Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 17, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US45259L2051

IB Impact BioMedical, Inc. logo Thin data Jul 17, 2026

Impact BioMedical, Inc.

IBO · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $1.01 · Strongly overvalued (−82%)
!Quality 35/100
!Weak Growth (revenue 3y −13.8 %/yr)
!negative free cash flow
!Trails peers (1/6)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Impact BioMedical, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$62.78 $4.58 Fair Value $1.01 Sep 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

24‑month range $4.58 – $62.78 · fair‑value band $0.7595 – $1.52 · the $5.65 price screens above the $1.01 fair value. Dashed = 300-day average. As of Jul 17, 2026.

Follow Impact BioMedical in your weekly email

Every Wednesday you see whether Impact BioMedical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.

Show more

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc

Stock analysis

Impact BioMedical, Inc. (IBO) currently trades at $5.65, while our model-based Fair Value estimate is $1.01, implying the stock looks roughly 457.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: $0.7595 (bear) to $1.52 (bull), the price of $5.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Impact BioMedical, Inc. reported revenue of $32.0K in FY2025 versus $50.0K in FY2021, a compound −10.6%/yr. Reported net income was −$11.8M in FY2025.

Key figures

Market cap $54.1M · EPS (TTM) $−0.2900 · Return on equity −120% · Return on assets (EBIT) −8.9% · Operating margin −32,700% · Revenue (TTM) $39.0K · Free cash flow −$1.9M · Net cash $3.0K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −82%, IBO screens richer than that median.

Fair Value models

Bear $0.7595 Fair Value $1.01 Bull $1.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0600 $0.0800 $0.1200 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.0600 $0.0800 $0.1200 51

Open the full fair value analysis →

Notify me when IBO reaches fair value

Put IBO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 35/100

Of which business quality 37 · Market factors (momentum, volatility) 9

Profitability 0
Margins and returns on capital today
Quality Growth 2
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 17
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 50
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−98.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,370.0% (2021) → −13,343.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IBO screens 458% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Impact BioMedical, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −99% · Bottom 25%
Profitability
Return on assets −19% · Below median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.29× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Impact BioMedical, Inc. · Fair Value
$1.01 −458%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Impact BioMedical, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/IBO

Frequently asked questions

Is Impact BioMedical, Inc. (IBO) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of $1.01 versus a price of $5.65, about −82% upside (overvalued).
What is the fair value of IBO?
Our model-based fair value for Impact BioMedical, Inc. is $1.01 (as of Jul 17, 2026), built from audited fundamentals. The current price: $5.65.
What is the quality score of IBO?
Impact BioMedical, Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Impact BioMedical, Inc. (IBO)?
Our model-based price target is the fair value of $1.01 (as of Jul 17, 2026) from 1 valuation models. Cautious scenario $0.7595, optimistic scenario $1.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Impact BioMedical, Inc. stock forecast for 2026?
Our models put fair value at $1.01, about −82% upside versus a price of $5.65 (overvalued). Cautious scenario $0.7595, optimistic scenario $1.52. The calculation is refreshed regularly with new filings.
What is the revenue of Impact BioMedical, Inc. (IBO)?
Impact BioMedical, Inc. reported trailing-twelve-month revenue of about $39.0K (latest available figure, as of Jul 17, 2026).
What is the intrinsic value of Impact BioMedical, Inc. (IBO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Impact BioMedical, Inc. it is $1.01 per share (as of Jul 17, 2026), against a price of $5.65. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Impact BioMedical, Inc. stock overvalued or undervalued in 2026?
As of Jul 17, 2026, IBO trades above its calculated fair value: price $5.65, fair value $1.01, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IBO?
No. The price is what the market pays today ($5.65); the fair value is what the company's own numbers justify ($1.01). For Impact BioMedical, Inc. the two are $4.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is Impact BioMedical, Inc. worth?
The market values Impact BioMedical, Inc. at about $54.1M (market capitalisation, as of Jul 17, 2026). Per share that is $5.65; our models calculate a fair value of $1.01 per share.
What do the bullish and bearish scenarios say about IBO?
Our models span a range for Impact BioMedical, Inc.: cautious scenario $0.7595, base $1.01, optimistic $1.52 per share (as of Jul 17, 2026, price $5.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Impact BioMedical, Inc. (IBO)?
Balance-sheet figures for Impact BioMedical, Inc. (as of Jul 17, 2026): return on equity −119.7%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is IBO from its 52-week high?
Impact BioMedical, Inc. trades at $5.65, about 43% below its 52-week high of $9.87 and 11% above the low of $5.08 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.01 is for.
Which stocks are comparable to Impact BioMedical, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Impact BioMedical, Inc. stock attractive at the current price?
The data as of Jul 17, 2026: price $5.65, calculated fair value $1.01 (−82%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IBO calculated?
We run Impact BioMedical, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.01, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Impact BioMedical, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Impact BioMedical, Inc. (IBO)?
The closing price on Sep 24, 2026 was $5.65. Our model-based fair value is $1.01, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Impact BioMedical, Inc. right now?
The price sits above even our optimistic bull case ($1.52). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.7595 to $1.52) leaves room in how you read the outcome.

Key figures of Impact BioMedical, Inc.

How large is the market capitalisation of Impact BioMedical, Inc. (IBO)?
The market capitalisation of Impact BioMedical, Inc. is $54.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Impact BioMedical, Inc. (IBO)?
Earnings per share at Impact BioMedical, Inc. are $−0.2900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Impact BioMedical, Inc. (IBO)?
The return on equity (ROE) of Impact BioMedical, Inc. is −120% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Impact BioMedical, Inc. (IBO)?
On an EBIT basis the return on assets of Impact BioMedical, Inc. is −8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Impact BioMedical, Inc. (IBO)?
The operating margin of Impact BioMedical, Inc. is −32,700% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Impact BioMedical, Inc. (IBO) generate?
The free cash flow of Impact BioMedical, Inc. is −$1.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Impact BioMedical, Inc. (IBO) hold?
Impact BioMedical, Inc. holds more cash than debt, $3.0K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Impact BioMedical, Inc. in the live analysis

One click puts Impact BioMedical, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.